

# Special Issue

## Multidrug Resistance in the 2020's: A Threat in the Hospital and in the Community

### Message from the Guest Editors

Multidrug Resistance represent a major concern for public health and the pressure for hospitals and communities. During the ongoing COVID-19 pandemic, antibiotics and antifungals have been extensively used for the management of hospitalized patients infected with SARS-CoV-2. Unintended consequences of antimicrobial overuse include, among others, the increment of resistance and the circulation of multidrug-resistant organisms (MDROs). On the other hand, the management of hospitalized SARS-CoV-2 patients increases the risk of outbreak due to MDROs for several reasons, including the increased number of patients, increased length of hospital stay, extensive antibiotic use, lack of infection prevention and control measures and interruption of antimicrobial stewardship programs. In this Special Issue, we encourage colleagues to submit manuscripts related to the multidrug-resistant pathogens and relevant treatment—from hospital to communities. We also welcome manuscripts describing new methods and the adaption or creation of technologies for the study, prevention, and control of multidrug resistance.

---

### Guest Editors

Dr. Despoina Koulenti

Antimicrobial Optimisation Group, UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia

Prof. Dr. Stijn Blot

Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium

---

### Deadline for manuscript submissions

closed (31 July 2023)



**Microorganisms**

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.2**  
**CiteScore 7.7**  
**Indexed in PubMed**



[mdpi.com/si/156192](https://mdpi.com/si/156192)

*Microorganisms*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[microorganisms@mdpi.com](mailto:microorganisms@mdpi.com)

[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)





## Microorganisms

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.2  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)



## About the Journal

### Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

---

### Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2025).